AstraZeneca to spin-out early-stage antibiotic R&D into stand-alone company
Anglo-Swedish pharma major AstraZeneca is changing the structure of its small-molecule early-stage anti-infectives R&D in line with its strategy to sharpen its focus on three main therapy areas.
AstraZeneca will create a stand-alone subsidiary company, focused exclusively on the R&D of its early-stage antibiotic pipeline, including the novel gyrase inhibitor AZD0914, which is currently in Phase II for the treatment of gonorrhea. AstraZeneca will invest $40 million in the new company, which it anticipates will be led by and include staff from AstraZeneca’s Innovative Medicines Unit.
Antibiotics not a priority for the company
Pascal Soriot, AstraZeneca’s chief executive, has long made clear that antibiotics are not a priority for the company, while promising to look for ways to keep alive its research and development in the area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze